• Plans to raise capital within the next quarter
• Sentia wine testing device sales up 7% and test strip sales up 8% in Q1 2025
• Xprecia blood testing device sales up 1% but test strip sales down 13% in Q1 2025

Universal Biosensors Inc has reported its Q1 2025 results, with the key highlights being plans for a capital raise within the next quarter, strong growth in its Sentia wine testing business, and a decline in its Xprecia blood testing strip sales. The company's Sentia wine testing devices saw a 7% increase in Q1 2025 compared to Q4 2024, while test strip sales grew by 8% over the same period. This was driven by the new sales team, remediated assays, an increased presence at trade shows, and a more targeted sales strategy. In contrast, the Xprecia blood testing devices saw a 1% increase in Q1 2025, but test strip sales were down 13% due to the loss of a customer tender in Spain in late 2023. The company has signed 12 new distribution agreements in 2024 and 3 so far in 2025, as well as winning 1 tender and having 10 tenders ongoing, with 14 more tender opportunities about to commence. The company is also progressing the development of its AQUASCOUT water testing platform, which is due for launch in H2 2025 and addresses key issues associated with current methods for heavy metal detection in water samples.

Universal Biosensors Inc plans to raise capital within the next quarter to support the continued growth and development of its business. The company is working on and has well-developed plans progressed with a number of options, with the quantum and structure to be confirmed.